ANDERSON-FABRY DISEASE: MANIFESTATION AND PROGNOSIS
Abstract
The aim of the study was to describe diagnostic and treatment experience of Fabry disease in Ukraine, rare inherited multisystem metaboliс disorder with chronic kidney insufficiency as one of signs. The diagnosis was found in nine years old boy with acroparestesia and multiply angiokeratomas after enzymodiagnostic test (determination of lysosomal enzyme alpha-galactosidase A activity level in peripheral blood leucocytes). The parents gave consent to examine of the other child in family, 19 years old boy with myeloradiculonevritis and inferior paraparesis, and glomerulonephritis presented by proteinuria. Fabry disease was confirmed in proband by special enzymodiagnostic test. Clinical-genealogical analysis was exposed by the "phenomenon of grandfather": grandfather exitus from End Stage Renal Disease, probably due renal manifestation of Fabry disease. Enzyme replacement therapy was stabilized patient state, decreased the proteinuria level and saved the renal function. Early and classic signs of Fabry disease which allows to suspect a genetic anomaly were presented in article. Information about Fabry disease physician followed by in-time diagnosis and onset of specific therapy those provide favorable disease course, social adaptation and rehabilitation of patient, effective medical-genetic consultation in gen-compromised families.
Downloads
References
Anderson-Fabry disease: сlinical manifestations of disease in female heterozygotes / C. Whybra, C. Kampmann, I. Willers [et al.] // J. Inherit. Metab. Dis. – 2001. - Vol. 24. - P. 715-724.
Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry / M. R. Patel, F. Cecchi, M. Cizmarik [et al.] // J. Am. Coll. Cardiol. – 2011. – Vol. 57. – P. 1093–1099.
Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey / U. Ramaswami, C. Whybra, R. Parini [et al.] // Acta Paediatr. – 2006. – Vol. 95. - P. 86-92.
Desnick R. J. Alpha-Galactosidase A deficiency: Fabry disease / R. J. Desnick, Y. A. Ioannou, C. M. Eng // The metabolic and molecular basis of inherited disease: 8th edition. Eds C. R. Scriver, A. L. Beaudet, W. S. Sly, D. Valle. - New York : McGraw- Hill; 2001. – P. 3733–3774.
Enzyme replacement therapy with agalsidase alfa in patients with Fabry’s disease: an analysis of registry data / A. Mehta, M. Beck, P. Elliott [et al.] // Lancet. – 2009. - Vol. 374. – Р. 1886-1896.
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy / R. Schiffmann, D. G. Warnock, M. Banikazemi [et al.] // Nephrol. Dial. Transplant. – 2009. – Vol. 24. – P. 2102-2111.
Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorragica nodularis (Purpura papulosa hemorrhagica Hebrae) / J. Fabry // Arch. Dermatol. Syphilol. – 1898. – Vol. 43. – P. 187-200.
Germain D. P. Fabry disease [Електронний ресурс] / D. P. Germain // Orphanet J. Rare Dis. – 2010. – Vol. 5. - Режим доступу : http://www.ojrd.com/content/5/1/30
Renal manifestations of Fabry disease / D. G. Warnock, C. Valbuena, M. West, J. P. Oliveira // Fabry disease. Eds D. Elstein, G. Altarescu, M. Beck. - Dordrecht, Heidelberg, London, New-York : Springer; 2010. – P. 211-244.
Suzuki K. Enzymic diagnosis of sphingolipidoses / K. Suzuki // Methods in enzymology. - Akademic Press: NY, San-Francisco, London; 1978. - P. 475-480.
Torra R. Renal manifestations in Fabry disease and therapeutic options / R. Torra // Kidney Int. Suppl. – 2008. – S. 29-32.
Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing / R. Schiffmann, H. Askari, M. Timmons [et al.] // J. Am. Soc. Nephrol. – 2007. – Vol. 18. – Р. 1576-1583.
Wenger D. A. Screening for lysosomal disorders / D. A. Wenger, C. Williams // Techniques in diagnostics of human biochemical genetics. - Wiley-Liss : NY; 1991. - P. 587-619.
